To characterize PC targets for potential treatment options in systemic AL amyloidosis with an aberrant PC population as the amyloidogenic clone, we evaluated the expression levels of SLAMF7, CD52, CD30, CD22, and CD20 on BM PCs by MFC in an increased number of patients (Fig. 3), 20. The gene discussed is CD22; the disease is primary systemic amyloidosis.